. Author manuscript; available in PMC: 2015 Dec 22.

Published in final edited form as: J Pharmacol Toxicol Methods. 2008 Aug 3;58(3):222–232. doi: 10.1016/j.vascn.2008.07.003

Table 1.

Quantitative Analysis of Beta-Galatosidase Transgene Expression After Systemic Administration of Recombinant Adenovirus by Different Routes.^a

		ng beta-galactosidase/mg protein

	Time (days)	Jugular	Tail

Liver	0.25	415.8 ± 57.06	193.1 ± 23.36
	1	3,731 ± 1,163	3,157 ± 1,444
	4	54,306 ± 7,265	62,273 ± 10,560
Spleen	0.25	227.7 ± 47.58	32.62 ± 19.57
	1	367.1 ± 144.0	110.3 ± 41.06
	4	44.79 ± 11.37	41.48 ± 2.43
Kidney	0.25	N.D.	N.D.
	1	6.52 ± 2.46	N.D.
	4	10.34 ± 1.41	1.89 ± 0.49

Data were obtained from tissue homogenates and reflect average values ± standard errors of the means from 4 animals per treatment group. N.D. - None detected. Sample fell below the detection limit of the assay (30 pg/mg protein).

Jugular: Data obtained from animals given 5.7 × 10¹² vp/kg of adenovirus expressing beta-galactosidase into the jugular vein through an implanted catheter.

Tail: Data obtained from animals given 5.7 × 10¹² vp/kg of adenovirus expressing beta-galactosidase by direct injection into the lateral tail vein.